Code,Set,Journal,Title,Authors,Year,Number,Volume,"First Page","Last Page"
1,Internal,"Biochem. Biophys. Res. Commun.","Reversal of P-glycoprotein-mediated MDR by 5,7,3',4',5'-pentamethoxyflavone and SAR","Choi, C.H.; Kim, J.H.; Kim, S.H.",2004,320,3,672,679
2,Internal,"Chem. Res. Toxicol.","Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4","Wang, E.; Lew, K.; Barecki, M.; Casciano, C.N.; Clement, R.P.; Johnson, W.W.",2001,14,12,1596,1603
3,Internal,"Clin. Cancer Res.","VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein","Minderman, H.; O'Loughlin, K.L.; Pendyala, L.; Baer, M.R.",2004,10,5,1826,1834
4,Internal,"Drug Metab. Dispos.","Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro","Wandel, C.; Kim, R.B.; Guengerich, F.P.; Wood, A.J.",2000,28,8,895,898
5,Internal,"Drug Metab. Dispos.","The anthelminthic agent albendazole does not interact with p-glycoprotein","Merino, G.; Alvarez, A.I.; Prieto, J.G.; Kim, R.B.",2002,30,4,365,369
6,Internal,"Drug Metab. Dispos.","Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1","Chen, C.; Mireles, R.J.; Campbell, S.D.; Lin, J.; Mills, J.B.; Xu, J.J.; Smolarek, T.A.",2005,33,4,537,546
7,Internal,"Drug Metab. Dispos.","In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates","Rautio, J.; Humphreys, J.E.; Webster, L.O.; Balakrishnan, A.; Keogh, J.P.; Kunta, J.R.; Serabjit-Singh, C.J.; Polli, J.W.",2006,34,5,786,792
8,Internal,"Drug Metab. Dispos.","In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system","Feng, B.; Mills, J.B.; Davidson, R.E.; Mireles, R.J.; Janiszewski, J.S.; Troutman, M.D.; de Morais, S.M.",2008,36,2,268,275
9,Internal,"Eur. J. Pharm. Sci.","Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.","Katoh, M.; Nakajima, M.; Yamazaki, H.; Yokoi, T.",2001,12,4,505,513
10,Internal,"Eur. J. Pharm. Sci.","Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein","Keogh, J.P.; Kunta, J.R.",2006,27,5,543,554
11,Internal,"Eur. J. Pharm. Sci.","The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux","Hayeshi, R.; Masimirembwa, C.; Mukanganyama, S.; Ungell, A.L.",2006,29,1,70,81
13,Internal,"Cancer Res.","Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979","Dantzig, A.H.; Shepard, R.L.; Cao, J.; Law, K.L.; Ehlhardt, W.J.; Baughman, T.M.; Bumol, T.F.; Starling, J.J.",1996,56,18,4171,4179
14,Internal,"Jpn. J. Pharmacol.","Reversal of multidrug resistance in human leukemia K562 by tamolarizine, a novel calcium antagonist","Miyake, N.; Fujita, R.; Ishikawa, M.; Takayanagi, M.; Takayanagi, Y.; Sasaki, K.",2000,86,3,265,268
15,Internal,"J. Med. Chem.","Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery","Schwab, D.; Fischer, H.; Tabatabaei, A.; Poli, S.; Huwyler, J.",2003,46,9,1716,1725
16,Internal,"J. Med. Chem.","Substituted 4-acylpyrazoles and 4-acylpyrazolones: synthesis and multidrug resistance-modulating activity","Chiba, P.; Holzer, W.; Landau, M.; Bechmann, G.; Lorenz, K.; Plagens, B.; Hitzler, M.; Richter, E.; Ecker, G.",1998,41,21,4001,4011
17,Internal,"J. Pharm. Sci.","Characterization of dexloxiglumide in vitro biopharmaceutical properties and active transport","Tolle-Sander, S.; Grill, A.; Joshi, H.; Kapil, R.; Persiani, S.; Polli, J.E.",2003,92,10,1968,1980
18,Internal,"J. Pharm. Sci.","Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug","Toyobuku, H.; Tamai, I.; Ueno, K.; Tsuji, A.",2003,92,11,2249,2259
19,Internal,"J. Biomol. Screening","High-Throughput Screening for Daunorubicin-Mediated Drug Resistance Identifies Mometasone Furoate as a Novel ABCB1-Reversal Agent","Winter, S.S.; Lovato, M.L.; Khawaja, H.M.; Edwards B.S.; Steele I.D.; Young, S.M.; Oprea, T.I.; Skylar, L.A.; Larson, R.S.",2008,13,3,185,193
20,Internal,"J. Pharmacol. Exp. Ther.","Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein","Pauli-Magnus, C.; von Richter, O.; Burk, O.; Ziegler, A.; Mettang, T.; Eichelbaum, M.; Fromm, M.F.",2000,293,2,376,378
21,Internal,"J. Pharmacol. Exp. Ther.","Rational use of in vitro P-glycoprotein assays in drug discovery","Polli, J.W.; Wring, S.A.; Humphreys, J.E.; Huang, L.; Morgan, J.B.; Webster, L.O.; Serabjit-Singh, C.S.",2001,299,2,620,628
22,Internal,"J. Pharmacol. Exp. Ther.","Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs","Mahar Doan, K.M.; Humphreys, J.E.; Webster, L.O.; Wring, S.A.; Shampine, L.J.; Serabjit-Singh, C.J.; Adkison, K.K.; Polli, J.W.",2002,303,3,1029,1037
23,Internal,"J. Pharmacol. Exp. Ther.","Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana","Zhu, H.J.; Wang, J.S.; Markowitz, J.S.; Donovan, J.L.; Gibson, B.B.; Gefroh, H.A.; Devane, C.L.",2006,317,2,850,857
24,Internal,"J. Vet. Pharmacol. Ther.","Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein","Griffin, J.; Fletcher, N.; Clemence, R.; Blanchflower, S.; Brayden, D.J.",2005,28,3,257,265
25,Internal,"Mol. Pharmacol.","Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein","Ekins, S.; Kim, R.B.; Leake, B.F.; Dantzig, A.H.; Schuetz, E.G.; Lan L.B.; Yasuda K.; Shepard, R.L.; Winter, M.A.; Schuetz, J.D.; Wikel, J.H.; Wrighton, S.A.",2002,61,5,964,973
26,Internal,"Mol. Pharmacol.","Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates","Ekins, S.; Kim, R.B.; Leake, B.F.; Dantzig, A.H.; Schuetz, E.G.; Lan, L.B.; Yasuda, K.; Shepard, R.L.; Winter, M.A.; Schuetz, J.D.; Wikel, J.H.; Wrighton, S.A.",2002,61,5,974,981
27,Internal,"Naunyn-Schmiedeberg's Arch. Pharmacol.","A novel screening strategy to identify ABCB1 substrates and inhibitors","von Richter, O.; Glavinas, H.; Krajcsi, P.; Liehner, S.; Siewert, B.; Zech, K.",2009,379,1,11,26
28,Internal,http://pdsp.med.unc.edu/indexR.html,,,,,,,
29,Internal,"Pfluegers Arch.","P-glycoprotein inhibition by glibenclamide and related compounds","Golstein, P.E.; Boom, A.; van Geffel, J.; Jacobs, P.; Masereel, B.; Beauwens, R.",1999,437,5,652,660
30,Internal,"Pharm. Res.","Chemogenomic analysis identifies geldanamycins as substrates and inhibitors of ABCB1","Huang, Y.; Blower, P.E.; Liu, R.; Dai, Z.; Pham, A.N.; Moon, H.; Fang, J.; Sadée, W.",2007,24,9,1702,1712
31,Internal,"Pharm. Res.","Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein","Kim, R.B.; Wandel, C.; Leake, B.; Cvetkovi,c M.; Fromm, M.F.; Dempsey, P.J.; Roden, M.M.; Belas, F.; Chaudhary, A.K.; Roden, D.M.; Wood, A.J.; Wilkinson, G.R.",1999,16,3,408,414
32,Internal,"Pharm. Res.","Rapid assessment of P-glycoprotein inhibition and induction in vitro","Perloff, M.D.; Störmer, E.; von Moltke, L.L.; Greenblatt, D.J.",2003,20,8,1177,1184
33,Internal,Psychopharmacology,"Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein","Wang, J.S.; Zhu, H.J.; Markowitz, J.S.; Donovan, J.L.; DeVane, C.L.",2006,187,4,415,423
34,Internal,"Toxicol. Appl. Pharmacol.","Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein","Bain, L.J.; LeBlanc, G.A.",1996,141,1,288,298
35,Internal,"Cancer Lett.","Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519","Che, X.F.; Nakajima, Y.; Sumizawa, T.; Ikeda, R.; Ren, X.Q.; Zheng, C.L.; Mukai, M.; Furukawa, T.; Haraguchi, M.; Gao, H.; Sugimoto, Y.; Akiyama S.",2002,187,1,111,119
36,Internal,Blood,"Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies","Merlin, J.L.; Guerci, A.; Marchal, S.; Missoum, N.; Ramacci, C.; Humbert, J.C.; Tsuruo, T.; Guerci, O.",1994,84,1,262,269
37,Internal,"Biochem. Pharmacol.","Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance","Hofmann, J.; Gekeler, V.; Ise, W.; Noller, A.; Mitterdorfer, J.; Hofer, S.; Utz, I.; Gotwald, M.; Boer, R.; Glossmann, H. Grunicke, H.H.",1995,49,5,603,609
38,Internal,"Cancer Chemother. Pharmacol.","New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833","Naito, M.; Tsuruo, T.",1997,40,S,20,24
39,Internal,"Biochem. Pharmacol.","Structure-activity relationship of verapamil analogs and reversal of multidrug resistance","Toffoli, G.; Simone, F.; Corona, G.; Raschack, M.; Cappelletto, B.; Gigante, M.; Boiocchi, M.",1995,50,8,1245,1255
40,Internal,"Cancer Res.","P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies","Wandel, C.; Kim, R.B.; Kajiji, S.; Guengerich, P.; Wilkinson, G.R.; Wood, A.J.",1999,59,16,3944,3948
41,Internal,"Eur. J. Pharmacol.","Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel","Kwak, J.O.; Lee, S.H.; Lee, G.S.; Kim, M.S.; Ahn, Y.G.; Lee, J.H.; Kim, S.W.; Kim, K.H.; Lee, M.G.",2010,627,1,92,98
42,External,"J. Med. Chem.","A comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of anthranilamide derivatives that are multidrug resistance modulators","Labrie, P.; Maddaford, S.P.; Fortin, S.; Rakhit, S.; Kotra, L.P.; Gaudreault, R.C.",2006,49,26,7646,7660
43,External,"J. Med. Chem.","Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance","Wang, S.; Folkes, A.; Chuckowree, I.; Cockcroft, X.; Sohal, S.; Miller, W.; Milton, J.; Wren, S.P.; Vicker, N.; Depledge, P.; Scott, J.; Smith, L.; Jones, H.; Mistry, P.; Faint, R.; Thompson, D.; Cocks, S.",2004,47,6,1329,1338
44,External,"J. Med. Chem.","Three-dimensional quantitative structure-activity relationship analysis of propafenone-type multidrug resistance modulators: influence of variable selection on test set predictivity","Fleischer, R.; Wiese, M.",2003,46,23,4988,5004
45,External,"J. Med. Chem.","Substituted 4-acylpyrazoles and 4-acylpyrazolones: synthesis and multidrug resistance-modulating activity","Chiba, P.; Holzer, W.; Landau, M.; Bechmann, G.; Lorenz, K.; Plagens, B.; Hitzler, M.; Richter, E.; Ecker, G.",1998,41,21,4001,4011
46,External,"J. Med. Chem.","Synthesis and in vitro multidrug resistance modulating activity of a series of dihydrobenzopyrans and tetrahydroquinolines","Hiessböck, R.; Wolf, C.; Richter, E.; Hitzler, M.; Chiba, P.; Kratzel, M.; Ecker, G.",1999,42,11,1921,1926
47,External,"J. Med. Chem.","Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents","Colabufo, N.A.; Berardi, F.; Perrone, R.; Rapposelli, S.; Digiacomo, M.; Vanni, M.; Balsamo, A.",2008,51,5,1415,1422
49,External,"J. Med. Chem.","Biological evaluation of bishydroxymethyl-substituted cage dimeric 1,4-dihydropyridines as a novel class of p-glycoprotein modulating agents in cancer cells","Richter, M.; Molnár, J.; Hilgeroth, A.",2006,49,9,2838,2840
51,External,"J. Med. Chem.","New potent P-glycoprotein inhibitors carrying a polycyclic scaffold","Bisi, A.; Gobbi, S.; Rampa, A.; Belluti, F.; Piazzi, L.; Valenti, P.; Gyemant, N.; Molnár, J.",2006,49,11,3049,3051
52,External,"Bioorg. Med. Chem. Lett.","Synthesis and evaluation of hapalosin and analogs as MDR-reversing agents","O'Connell, C.E.; Salvato, K.A.; Meng, Z.; Littlefield, B.A.; Schwartz, C.E.",1999,9,11,1541,1546
53,External,"Eur. J. Med. Chem.","Anti-calmodulin acridone derivatives modulate vinblastine resistance in multidrug resistant (MDR) cancer cells","Hegde, R.; Thimmaiah, P.; Yerigeri, M.C.; Krishnegowda, G.; Thimmaiah, K.N.; Houghton, P.J.",2004,39,2,161,167
54,External,"Bioorg. Med. Chem. Lett.","2,4,5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 1","Sarshar, S.; Zhang, C.; Moran, E.J.; Krane, S.; Rodarte, J.C.; Benbatoul, K.D.; Dixon, R.; Mjalli, A.M.",2000,10,23,2599,2601
55,External,"Bioorg. Med. Chem. Lett.","2,4,5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 2","Zhang, C.; Sarshar, S.; Moran, E.J.; Krane, S.; Rodarte, J.C.; Benbatoul, K.D.; Dixon, R.; Mjalli, A.M.",2000,10,23,2603,2605
56,External,"Bioorg. Med. Chem.","In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2)","Labrie, P.; Maddaford, S.P.; Lacroix, J.; Catalano, C.; Lee, D.K.; Rakhit, S.; Gaudreault, R.C.",2007,15,11,3854,3856
57,External,"Bioorg. Med. Chem.","Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors","Müller, H.; Pajeva, I.K.; Globisch, C.; Wiese, M.",2008,16,5,2448,2462
58,External,"Bioorg. Med. Chem.","New derivatives of silybin and 2,3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity","Dzubák, P.; Hajdúch, M.; Gazák, R.; Svobodová, A.; Psotová, J.; Walterová, D.; Sedmera, P.; Kren, V.",2006,14,11,3793,3810
59,External,"Bioorg. Med. Chem.","New functional assay of P-glycoprotein activity using Hoechst 33342","Müller, H.; Klinkhammer, W.; Globisch, C.; Kassack, M.U.; Pajeva, I.K.; Wiese, M.",2007,15,23,7470,7479
60,External,"Mol. Pharmacol.","Quantitative structure-activity relationship of multidrug resistance reversal agents","Klopman, G.; Shi, L.M.; Ramu, A.",1997,52,2,323,324
61,Internal,"J. Med. Chem.","Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring","Lee, Y.; Yeo, H.; Liu, S.H.; Jiang, Z.; Savizky, R.M.; Austin, D.J.; Cheng, Y.C.",2004,47,22,5555,5566
62,Internal,"J. Med. Chem.","Self-organizing maps for identification of new inhibitors of P-glycoprotein","Kaiser, D.; Terfloth, L.; Kopp, S.; Schulz, J.; de Laet, R.; Chiba, P.; Ecker, G.F.; Gasteiger, J.",2007,50,7,1698,1702
63,Internal,"J. Med. Chem.","2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: effect of different basic side-chains on their biological properties","Colabufo, N.A.; Berardi, F.; Perrone, R.; Rapposelli, S.; Digiacomo, M.; Vanni, M.; Balsamo, A.",2008,51,23,7602,7612
64,Internal,"J. Med. Chem.","C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump","Leonessa, F.; Kim, J.H.; Ghiorghis, A.; Kulawiec, R.J.; Hammer, C.; Talebian, A.; Clarke, R.",2002,45,2,390,398
65,External,"J. Med. Chem.","Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells","Chan, K.F.; Zhao, Y.; Burkett, B.A.; Wong, I.L.; Chow, L.M.; Chan, T.H.",2006,49,23,6742,6759
